OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models
OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models Introduction: OncoWuXi Express will continue to keep you informed about...
Continue ReadingKnowledge Library
Creating a Biological Switch Using DEL Technology
In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to...
Continue Reading
Recent Insights into Immuno-Oncology
The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...
Continue Reading
Armoring CAR-T Therapy with PD-1 Blockade
The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...
Continue Reading AACR 2024 Posters: Sneak Peek
AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for...
Continue Reading Pioneering Advanced Modalities in Early Drug Discovery
New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...
Continue Reading
Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently...
On-target, off-tumor toxicity is a specific type of toxic side effect that limits the anticancer applicability of chimeric antigen receptor...
Continue Reading
PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro...
Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA)....
Continue Reading